# Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma

> **NCT05260619** · PHASE2 · RECRUITING · sponsor: **Seoul National University Bundang Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Central Nervous System Lymphoma

## Interventions

- **DRUG:** lenalidomide

## Key facts

- **NCT ID:** NCT05260619
- **Lead sponsor:** Seoul National University Bundang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-01
- **Primary completion:** 2027-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2022-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05260619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05260619, "Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05260619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*